Author

Kong Hyejeong

Observed name: Hyejeong Kong

Institutions: Soonchunhyang University, Soonchunhyang University Hospital Cheonan

Observed institutions: Soonchunhyang University, Soonchunhyang University Hospital Cheonan

ORCID: 0000-0002-3512-8472

Observed ORCID: 0000-0002-3512-8472

OpenAlex ID: A5132888291

In Vivo and In Vitro Anticancer Activity of Doxorubicin-loaded DNA-AuNP Nanocarrier for the Ovarian Cancer Treatment

2020 · Chang-Seuk Lee, Tae Kim, et al. · Cancers · 47

FOXA1 in Ovarian Cancer: A Potential Therapeutic Target to Enhance Immunotherapy Efficacy

2026 · Taewan Kim, Jaesung Ryu, et al. · International Journal of Molecular Sciences · 1

Abstract 7763: FOXA1 in ovarian cancer: Therapeutic target and immunotherapy enhancer

2026 · Taewan Kim, Baek MooJun, et al. · Cancer Research

Abstract 5777: Functional role of PLK1 in colorectal cancer progression and its potential to chemoresistance

2026 · Kong Hyejeong, Baek MooJun, et al. · Cancer Research

Abstract 5172: Mechanistic insights into PLK1 target inhibition in ovarian cancer: Functional suppression and PROTAC-based therapeutic agents

2026 · jaesung Ryu, Baek MooJun, et al. · Cancer Research

Abstract 3432: Role of M2 macrophages in chemoresistance about the tumor microenvironment of epithelial ovarian cancer

2026 · Jaesung Ryu, Baek MooJun, et al. · Cancer Research

Works count: 6

Citation count: 48

H-index: 1

I10-index: 1